<!DOCTYPE html>
<html lang="" xml:lang="">
<head>

  <meta charset="utf-8" />
  <meta http-equiv="X-UA-Compatible" content="IE=edge" />
  <title>Chapter 5 Lower Extremity Occlusive Disease | Vascular Surgery Board Review</title>
  <meta name="description" content="This is an ebook version of board review content produced for Audible Bleeding: The Vascular Surgery Podcast" />
  <meta name="generator" content="bookdown 0.24 and GitBook 2.6.7" />

  <meta property="og:title" content="Chapter 5 Lower Extremity Occlusive Disease | Vascular Surgery Board Review" />
  <meta property="og:type" content="book" />
  <meta property="og:url" content="https://adam-mdmph.github.io/VS-Board-Review/" />
  
  <meta property="og:description" content="This is an ebook version of board review content produced for Audible Bleeding: The Vascular Surgery Podcast" />
  <meta name="github-repo" content="https://github.com/adam-mdmph/VS-Board-Review" />

  <meta name="twitter:card" content="summary" />
  <meta name="twitter:title" content="Chapter 5 Lower Extremity Occlusive Disease | Vascular Surgery Board Review" />
  
  <meta name="twitter:description" content="This is an ebook version of board review content produced for Audible Bleeding: The Vascular Surgery Podcast" />
  

<meta name="author" content="Editors: Adam Johnson, MD, MPH; Matt Smith, MD, PhD; and Audible Bleeding" />


<meta name="date" content="2022-02-12" />

  <meta name="viewport" content="width=device-width, initial-scale=1" />
  <meta name="apple-mobile-web-app-capable" content="yes" />
  <meta name="apple-mobile-web-app-status-bar-style" content="black" />
  
  
<link rel="prev" href="abdominaliliacperipheral-aneurysms.html"/>
<link rel="next" href="mesenteric-disease.html"/>
<script src="libs/header-attrs-2.11/header-attrs.js"></script>
<script src="libs/jquery-3.6.0/jquery-3.6.0.min.js"></script>
<script src="https://cdn.jsdelivr.net/npm/fuse.js@6.4.6/dist/fuse.min.js"></script>
<link href="libs/gitbook-2.6.7/css/style.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-table.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-bookdown.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-highlight.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-search.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-fontsettings.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-clipboard.css" rel="stylesheet" />








<link href="libs/anchor-sections-1.0.1/anchor-sections.css" rel="stylesheet" />
<script src="libs/anchor-sections-1.0.1/anchor-sections.js"></script>



<style type="text/css">
/* Used with Pandoc 2.11+ new --citeproc when CSL is used */
div.csl-bib-body { }
div.csl-entry {
  clear: both;
}
.hanging div.csl-entry {
  margin-left:2em;
  text-indent:-2em;
}
div.csl-left-margin {
  min-width:2em;
  float:left;
}
div.csl-right-inline {
  margin-left:2em;
  padding-left:1em;
}
div.csl-indent {
  margin-left: 2em;
}
</style>

<link rel="stylesheet" href="style.css" type="text/css" />
</head>

<body>



  <div class="book without-animation with-summary font-size-2 font-family-1" data-basepath=".">

    <div class="book-summary">
      <nav role="navigation">

<ul class="summary">
<li><a href="./">VS Board Review</a></li>

<li class="divider"></li>
<li class="chapter" data-level="1" data-path="index.html"><a href="index.html"><i class="fa fa-check"></i><b>1</b> About</a>
<ul>
<li class="chapter" data-level="1.1" data-path="index.html"><a href="index.html#usage"><i class="fa fa-check"></i><b>1.1</b> Usage</a></li>
<li class="chapter" data-level="1.2" data-path="index.html"><a href="index.html#comments-questions-or-contributions"><i class="fa fa-check"></i><b>1.2</b> Comments, Questions or Contributions</a></li>
</ul></li>
<li class="chapter" data-level="2" data-path="cerebrovascular.html"><a href="cerebrovascular.html"><i class="fa fa-check"></i><b>2</b> Cerebrovascular</a>
<ul>
<li class="chapter" data-level="2.1" data-path="cerebrovascular.html"><a href="cerebrovascular.html#available-guidelines"><i class="fa fa-check"></i><b>2.1</b> Available Guidelines</a></li>
<li class="chapter" data-level="2.2" data-path="cerebrovascular.html"><a href="cerebrovascular.html#presentation-and-diagnosis"><i class="fa fa-check"></i><b>2.2</b> Presentation and Diagnosis</a></li>
<li class="chapter" data-level="2.3" data-path="cerebrovascular.html"><a href="cerebrovascular.html#management"><i class="fa fa-check"></i><b>2.3</b> Management</a>
<ul>
<li class="chapter" data-level="2.3.1" data-path="cerebrovascular.html"><a href="cerebrovascular.html#optimal-medical-therapy"><i class="fa fa-check"></i><b>2.3.1</b> <strong>Optimal medical therapy</strong></a></li>
<li class="chapter" data-level="2.3.2" data-path="cerebrovascular.html"><a href="cerebrovascular.html#carotid-endarterectomy"><i class="fa fa-check"></i><b>2.3.2</b> <strong>Carotid endarterectomy</strong></a></li>
<li class="chapter" data-level="2.3.3" data-path="cerebrovascular.html"><a href="cerebrovascular.html#carotid-artery-stenting"><i class="fa fa-check"></i><b>2.3.3</b> Carotid Artery Stenting</a></li>
<li class="chapter" data-level="2.3.4" data-path="cerebrovascular.html"><a href="cerebrovascular.html#management-of-uncommon-disease-presentations"><i class="fa fa-check"></i><b>2.3.4</b> Management of uncommon disease presentations</a></li>
</ul></li>
<li class="chapter" data-level="2.4" data-path="cerebrovascular.html"><a href="cerebrovascular.html#prospective-trials---must-reads"><i class="fa fa-check"></i><b>2.4</b> Prospective Trials - MUST READS</a></li>
</ul></li>
<li class="chapter" data-level="3" data-path="upper-extremity-and-thoracic-outlet.html"><a href="upper-extremity-and-thoracic-outlet.html"><i class="fa fa-check"></i><b>3</b> Upper Extremity and Thoracic Outlet</a>
<ul>
<li class="chapter" data-level="3.1" data-path="upper-extremity-and-thoracic-outlet.html"><a href="upper-extremity-and-thoracic-outlet.html#anatomy-exposure-of-vessels"><i class="fa fa-check"></i><b>3.1</b> Anatomy/ Exposure of Vessels</a></li>
<li class="chapter" data-level="3.2" data-path="upper-extremity-and-thoracic-outlet.html"><a href="upper-extremity-and-thoracic-outlet.html#epidemiology-etiology-and-diagnostic-evaluation"><i class="fa fa-check"></i><b>3.2</b> Epidemiology, etiology, and diagnostic evaluation</a></li>
<li class="chapter" data-level="3.3" data-path="upper-extremity-and-thoracic-outlet.html"><a href="upper-extremity-and-thoracic-outlet.html#operationsprocedures"><i class="fa fa-check"></i><b>3.3</b> Operations/Procedures</a></li>
<li class="chapter" data-level="3.4" data-path="upper-extremity-and-thoracic-outlet.html"><a href="upper-extremity-and-thoracic-outlet.html#vaso-occlusive-disease"><i class="fa fa-check"></i><b>3.4</b> Vaso-occlusive disease</a></li>
<li class="chapter" data-level="3.5" data-path="upper-extremity-and-thoracic-outlet.html"><a href="upper-extremity-and-thoracic-outlet.html#vasospastic-disorders"><i class="fa fa-check"></i><b>3.5</b> Vasospastic Disorders</a>
<ul>
<li class="chapter" data-level="3.5.1" data-path="upper-extremity-and-thoracic-outlet.html"><a href="upper-extremity-and-thoracic-outlet.html#ergotism"><i class="fa fa-check"></i><b>3.5.1</b> <strong>Ergotism</strong></a></li>
<li class="chapter" data-level="3.5.2" data-path="upper-extremity-and-thoracic-outlet.html"><a href="upper-extremity-and-thoracic-outlet.html#buergers-disease"><i class="fa fa-check"></i><b>3.5.2</b> <strong>Buerger’s Disease</strong></a></li>
<li class="chapter" data-level="3.5.3" data-path="upper-extremity-and-thoracic-outlet.html"><a href="upper-extremity-and-thoracic-outlet.html#large-artery-vasculitis"><i class="fa fa-check"></i><b>3.5.3</b> <strong>Large Artery Vasculitis</strong></a></li>
</ul></li>
<li class="chapter" data-level="3.6" data-path="upper-extremity-and-thoracic-outlet.html"><a href="upper-extremity-and-thoracic-outlet.html#aneurysmal-disease"><i class="fa fa-check"></i><b>3.6</b> Aneurysmal Disease</a></li>
<li class="chapter" data-level="3.7" data-path="upper-extremity-and-thoracic-outlet.html"><a href="upper-extremity-and-thoracic-outlet.html#occupational-vascular-disease"><i class="fa fa-check"></i><b>3.7</b> Occupational Vascular Disease</a>
<ul>
<li class="chapter" data-level="3.7.1" data-path="upper-extremity-and-thoracic-outlet.html"><a href="upper-extremity-and-thoracic-outlet.html#hand-arm-vibration-syndrome"><i class="fa fa-check"></i><b>3.7.1</b> Hand-Arm Vibration Syndrome </a></li>
<li class="chapter" data-level="3.7.2" data-path="upper-extremity-and-thoracic-outlet.html"><a href="upper-extremity-and-thoracic-outlet.html#hypothenar-hammer-syndrome"><i class="fa fa-check"></i><b>3.7.2</b> Hypothenar hammer syndrome</a></li>
<li class="chapter" data-level="3.7.3" data-path="upper-extremity-and-thoracic-outlet.html"><a href="upper-extremity-and-thoracic-outlet.html#environmental-exposures"><i class="fa fa-check"></i><b>3.7.3</b> Environmental Exposures</a></li>
<li class="chapter" data-level="3.7.4" data-path="upper-extremity-and-thoracic-outlet.html"><a href="upper-extremity-and-thoracic-outlet.html#sports-medicine"><i class="fa fa-check"></i><b>3.7.4</b> Sports Medicine</a></li>
</ul></li>
<li class="chapter" data-level="3.8" data-path="upper-extremity-and-thoracic-outlet.html"><a href="upper-extremity-and-thoracic-outlet.html#vascular-trauma-upper-extremity"><i class="fa fa-check"></i><b>3.8</b> Vascular Trauma-Upper Extremity</a></li>
<li class="chapter" data-level="3.9" data-path="upper-extremity-and-thoracic-outlet.html"><a href="upper-extremity-and-thoracic-outlet.html#compression-syndromes"><i class="fa fa-check"></i><b>3.9</b> Compression Syndromes</a>
<ul>
<li class="chapter" data-level="3.9.1" data-path="upper-extremity-and-thoracic-outlet.html"><a href="upper-extremity-and-thoracic-outlet.html#quadrilateral-space-syndrome"><i class="fa fa-check"></i><b>3.9.1</b> Quadrilateral space syndrome</a></li>
<li class="chapter" data-level="3.9.2" data-path="upper-extremity-and-thoracic-outlet.html"><a href="upper-extremity-and-thoracic-outlet.html#humeral-head-compression-of-axillary-artery"><i class="fa fa-check"></i><b>3.9.2</b> Humeral head compression of axillary artery</a></li>
</ul></li>
<li class="chapter" data-level="3.10" data-path="upper-extremity-and-thoracic-outlet.html"><a href="upper-extremity-and-thoracic-outlet.html#thoracic-outlet-syndrome"><i class="fa fa-check"></i><b>3.10</b> Thoracic Outlet Syndrome</a>
<ul>
<li class="chapter" data-level="3.10.1" data-path="upper-extremity-and-thoracic-outlet.html"><a href="upper-extremity-and-thoracic-outlet.html#anatomy"><i class="fa fa-check"></i><b>3.10.1</b> Anatomy</a></li>
<li class="chapter" data-level="3.10.2" data-path="upper-extremity-and-thoracic-outlet.html"><a href="upper-extremity-and-thoracic-outlet.html#diagnosis-and-evaluation"><i class="fa fa-check"></i><b>3.10.2</b> Diagnosis and Evaluation</a></li>
<li class="chapter" data-level="3.10.3" data-path="upper-extremity-and-thoracic-outlet.html"><a href="upper-extremity-and-thoracic-outlet.html#rib-resection-approaches"><i class="fa fa-check"></i><b>3.10.3</b> Rib Resection approaches</a></li>
<li class="chapter" data-level="3.10.4" data-path="upper-extremity-and-thoracic-outlet.html"><a href="upper-extremity-and-thoracic-outlet.html#vtos"><i class="fa fa-check"></i><b>3.10.4</b> vTOS</a></li>
<li class="chapter" data-level="3.10.5" data-path="upper-extremity-and-thoracic-outlet.html"><a href="upper-extremity-and-thoracic-outlet.html#atos"><i class="fa fa-check"></i><b>3.10.5</b> aTOS</a></li>
<li class="chapter" data-level="3.10.6" data-path="upper-extremity-and-thoracic-outlet.html"><a href="upper-extremity-and-thoracic-outlet.html#ntos"><i class="fa fa-check"></i><b>3.10.6</b> nTOS</a></li>
</ul></li>
</ul></li>
<li class="chapter" data-level="4" data-path="abdominaliliacperipheral-aneurysms.html"><a href="abdominaliliacperipheral-aneurysms.html"><i class="fa fa-check"></i><b>4</b> Abdominal/Iliac/Peripheral Aneurysms</a>
<ul>
<li class="chapter" data-level="4.1" data-path="abdominaliliacperipheral-aneurysms.html"><a href="abdominaliliacperipheral-aneurysms.html#pathogenesis-presentation-and-risk-factors"><i class="fa fa-check"></i><b>4.1</b> Pathogenesis, presentation and risk factors</a></li>
<li class="chapter" data-level="4.2" data-path="abdominaliliacperipheral-aneurysms.html"><a href="abdominaliliacperipheral-aneurysms.html#evaluation-and-diagnosis"><i class="fa fa-check"></i><b>4.2</b> Evaluation and Diagnosis</a>
<ul>
<li class="chapter" data-level="4.2.1" data-path="abdominaliliacperipheral-aneurysms.html"><a href="abdominaliliacperipheral-aneurysms.html#imaging"><i class="fa fa-check"></i><b>4.2.1</b> Imaging</a></li>
</ul></li>
<li class="chapter" data-level="4.3" data-path="abdominaliliacperipheral-aneurysms.html"><a href="abdominaliliacperipheral-aneurysms.html#management-1"><i class="fa fa-check"></i><b>4.3</b> Management</a>
<ul>
<li class="chapter" data-level="4.3.1" data-path="abdominaliliacperipheral-aneurysms.html"><a href="abdominaliliacperipheral-aneurysms.html#evar"><i class="fa fa-check"></i><b>4.3.1</b> EVAR</a></li>
<li class="chapter" data-level="4.3.2" data-path="abdominaliliacperipheral-aneurysms.html"><a href="abdominaliliacperipheral-aneurysms.html#open-repair"><i class="fa fa-check"></i><b>4.3.2</b> Open Repair</a></li>
<li class="chapter" data-level="4.3.3" data-path="abdominaliliacperipheral-aneurysms.html"><a href="abdominaliliacperipheral-aneurysms.html#ruptured-aneurysms"><i class="fa fa-check"></i><b>4.3.3</b> Ruptured Aneurysms</a></li>
</ul></li>
</ul></li>
<li class="chapter" data-level="5" data-path="lower-extremity-occlusive-disease.html"><a href="lower-extremity-occlusive-disease.html"><i class="fa fa-check"></i><b>5</b> Lower Extremity Occlusive Disease</a>
<ul>
<li class="chapter" data-level="5.1" data-path="lower-extremity-occlusive-disease.html"><a href="lower-extremity-occlusive-disease.html#pathophysiology"><i class="fa fa-check"></i><b>5.1</b> Pathophysiology</a></li>
<li class="chapter" data-level="5.2" data-path="lower-extremity-occlusive-disease.html"><a href="lower-extremity-occlusive-disease.html#intermittent-claudication"><i class="fa fa-check"></i><b>5.2</b> Intermittent Claudication</a>
<ul>
<li class="chapter" data-level="5.2.1" data-path="lower-extremity-occlusive-disease.html"><a href="lower-extremity-occlusive-disease.html#history-clinical-examination"><i class="fa fa-check"></i><b>5.2.1</b> History / Clinical Examination</a></li>
<li class="chapter" data-level="5.2.2" data-path="lower-extremity-occlusive-disease.html"><a href="lower-extremity-occlusive-disease.html#management-2"><i class="fa fa-check"></i><b>5.2.2</b> Management</a></li>
</ul></li>
</ul></li>
<li class="chapter" data-level="6" data-path="mesenteric-disease.html"><a href="mesenteric-disease.html"><i class="fa fa-check"></i><b>6</b> Mesenteric Disease</a>
<ul>
<li class="chapter" data-level="6.1" data-path="mesenteric-disease.html"><a href="mesenteric-disease.html#section"><i class="fa fa-check"></i><b>6.1</b> </a></li>
</ul></li>
<li class="chapter" data-level="7" data-path="renal.html"><a href="renal.html"><i class="fa fa-check"></i><b>7</b> Renal</a>
<ul>
<li class="chapter" data-level="7.1" data-path="renal.html"><a href="renal.html#section-1"><i class="fa fa-check"></i><b>7.1</b> </a></li>
</ul></li>
<li class="chapter" data-level="8" data-path="thoracic-aorta.html"><a href="thoracic-aorta.html"><i class="fa fa-check"></i><b>8</b> Thoracic Aorta</a>
<ul>
<li class="chapter" data-level="8.1" data-path="thoracic-aorta.html"><a href="thoracic-aorta.html#section-2"><i class="fa fa-check"></i><b>8.1</b> </a></li>
</ul></li>
<li class="chapter" data-level="9" data-path="venous-disease.html"><a href="venous-disease.html"><i class="fa fa-check"></i><b>9</b> Venous Disease</a>
<ul>
<li class="chapter" data-level="9.1" data-path="venous-disease.html"><a href="venous-disease.html#section-3"><i class="fa fa-check"></i><b>9.1</b> </a></li>
</ul></li>
<li class="chapter" data-level="10" data-path="vascular-trauma.html"><a href="vascular-trauma.html"><i class="fa fa-check"></i><b>10</b> Vascular Trauma</a>
<ul>
<li class="chapter" data-level="10.1" data-path="vascular-trauma.html"><a href="vascular-trauma.html#section-4"><i class="fa fa-check"></i><b>10.1</b> </a></li>
</ul></li>
<li class="chapter" data-level="11" data-path="angioaccess.html"><a href="angioaccess.html"><i class="fa fa-check"></i><b>11</b> Angioaccess</a>
<ul>
<li class="chapter" data-level="11.1" data-path="angioaccess.html"><a href="angioaccess.html#section-5"><i class="fa fa-check"></i><b>11.1</b> </a></li>
</ul></li>
<li class="chapter" data-level="12" data-path="complications-1.html"><a href="complications-1.html"><i class="fa fa-check"></i><b>12</b> Complications</a>
<ul>
<li class="chapter" data-level="12.1" data-path="complications-1.html"><a href="complications-1.html#section-6"><i class="fa fa-check"></i><b>12.1</b> </a></li>
</ul></li>
<li class="chapter" data-level="13" data-path="amputations.html"><a href="amputations.html"><i class="fa fa-check"></i><b>13</b> Amputations</a>
<ul>
<li class="chapter" data-level="13.1" data-path="amputations.html"><a href="amputations.html#section-7"><i class="fa fa-check"></i><b>13.1</b> </a></li>
</ul></li>
<li class="chapter" data-level="14" data-path="vascular-lab.html"><a href="vascular-lab.html"><i class="fa fa-check"></i><b>14</b> Vascular Lab</a>
<ul>
<li class="chapter" data-level="14.1" data-path="vascular-lab.html"><a href="vascular-lab.html#section-8"><i class="fa fa-check"></i><b>14.1</b> </a></li>
</ul></li>
<li class="chapter" data-level="15" data-path="vascular-medicine.html"><a href="vascular-medicine.html"><i class="fa fa-check"></i><b>15</b> Vascular Medicine</a>
<ul>
<li class="chapter" data-level="15.1" data-path="vascular-medicine.html"><a href="vascular-medicine.html#section-9"><i class="fa fa-check"></i><b>15.1</b> </a></li>
</ul></li>
<li class="chapter" data-level="16" data-path="endovascular.html"><a href="endovascular.html"><i class="fa fa-check"></i><b>16</b> Endovascular</a>
<ul>
<li class="chapter" data-level="16.1" data-path="endovascular.html"><a href="endovascular.html#section-10"><i class="fa fa-check"></i><b>16.1</b> </a></li>
</ul></li>
<li class="chapter" data-level="17" data-path="applied-science.html"><a href="applied-science.html"><i class="fa fa-check"></i><b>17</b> Applied Science</a>
<ul>
<li class="chapter" data-level="17.1" data-path="applied-science.html"><a href="applied-science.html#section-11"><i class="fa fa-check"></i><b>17.1</b> </a></li>
</ul></li>
<li class="chapter" data-level="" data-path="references.html"><a href="references.html"><i class="fa fa-check"></i>References</a></li>
<li class="divider"></li>
<li><a href="https://github.com/rstudio/bookdown" target="blank">Published with bookdown</a></li>

</ul>

      </nav>
    </div>

    <div class="book-body">
      <div class="body-inner">
        <div class="book-header" role="navigation">
          <h1>
            <i class="fa fa-circle-o-notch fa-spin"></i><a href="./">Vascular Surgery Board Review</a>
          </h1>
        </div>

        <div class="page-wrapper" tabindex="-1" role="main">
          <div class="page-inner">

            <section class="normal" id="section-">
<div id="lower-extremity-occlusive-disease" class="section level1" number="5">
<h1><span class="header-section-number">Chapter 5</span> Lower Extremity Occlusive Disease</h1>
<div id="pathophysiology" class="section level2" number="5.1">
<h2><span class="header-section-number">5.1</span> Pathophysiology</h2>
<p>24 Aug 2020: Nedal Katib and Danielle Bajakian</p>
<p><audio controls> <source src='https://traffic.libsyn.com/audiblebleeding/PAOD_part_1_postEQ.mp3' type='audio/mpeg'> Your browser does not support the audio tag;  for browser support, please see:  https://www.w3schools.com/tags/tag_audio.asp </audio></p>
<p><strong>What is Peripheral Arterial Disease (PAD) and what does it
encompass?</strong></p>
<p>Peripheral Arterial Disease encompasses extremity arterial disease but
generally is used to describe lower limb arterial occlusive disease.
PAOD is a more specific term and this encompasses atherosclerotic
disease of the lower limb arteries.</p>
<p>The disease has various presentations on a spectrum of asymptomatic
disease to intermittent claudication and finally chronic limb
threatening ischemia (CLTI) formerly known as Critical Limb Ischemia
(CLI) <span class="citation">(<a href="#ref-aboyans2017ESCGuidelines2018" role="doc-biblioref">Aboyans et al., 2018</a>)</span></p>
<p><strong>What is the underlying pathophysiology of PAOD?</strong></p>
<p>The underlying pathophysiology which results in occlusive arterial
disease of the lower limb has somewhat evolved over the last 50 years.
While atherosclerosis remains, the main pathological process resulting
in occlusive disease, smoking related atherosclerosis has in the last 30
years been confounded with the rising incidence of diabetes and in
addition an aging population with progressive arterial disease.</p>
<p>Atherosclerosis, in summary, begins with an injury to the intimal lining
of the arterial wall, which can result from smoking, hypertension or
advanced age and ultimately a chronic inflammatory reaction resulting in
plaque build up and calcification that may result in progressive
stenosis and occlusion or plaque rupture with acute occlusion.</p>
<p><strong>What are the risk factors for atherosclerosis?</strong></p>
<p>Modifiable:</p>
<ol style="list-style-type: decimal">
<li><p><strong><em>Smoking</em></strong></p>
<ul>
<li><p>The <strong>most significant modifiable risk factor</strong> for developing
peripheral arterial disease</p></li>
<li><p>Causes Endothelial dysfunction by reducing nitric oxide and
triggering reactive-oxygen species
<span class="citation">(<a href="#ref-unitedstatessurgeongeneralHealthConsequencesSmoking2014" role="doc-biblioref">United States Surgeon General, 2014</a>)</span></p></li>
<li><p>Causes a prothrombotic environment by causing an increase in
thromboxane A2 and decreasing Prostacyclin thus overall
resulting in an increased prothrombotic environment for
platelets.</p></li>
<li><p>Smoking has a stronger association with Intermittent
claudication than with Coronary Artery Disease!
<span class="citation">(<a href="#ref-gordonPredispositionAtherosclerosisHead1972" role="doc-biblioref">Gordon &amp; Kannel, 1972</a>)</span></p></li>
</ul></li>
<li><p><strong><em>Diabetes , Metabolic Syndrome and Insulin Resistance</em></strong></p>
<ul>
<li><p>Diabetes Mellitus, after smoking, is the most significant
modifiable risk factor for developing peripheral arterial
disease. Both insulin resistance and hyperinsulinemia are
independent risk factors for developing peripheral arterial
disease.</p></li>
<li><p>The Odds Risk for developing PAD in patients with DM ranges from
1.89 to 4.05.</p></li>
<li><p>An increase in HbA1C by 1% correlates with a 28% increase risk
of developing PAD. <span class="citation">(<a href="#ref-adlerUKPDS59Hyperglycemia2002" role="doc-biblioref">Adler et al., 2002</a>)</span></p></li>
</ul></li>
<li><p><strong><em>Hypertension</em></strong></p>
<ul>
<li><p>The <strong>most common</strong> cardiovascular risk factor worldwide.</p></li>
<li><p>The Incidence of PAD increases to 2.5-fold in patients with
Hypertension. <span class="citation">(<a href="#ref-kannelUpdateEpidemiologicFeatures1985" role="doc-biblioref">Kannel &amp; McGee, 1985</a>)</span></p></li>
</ul></li>
<li><p><strong><em>Dyslipidemia</em></strong></p>
<ul>
<li><p>A strong association has long been identified as a risk factor
for cardiovascular disease.</p></li>
<li><p>25% cardiovascular event reduction for each 39 mg/dL (1mmol/L)
reduction in LDL.
<span class="citation">(<a href="#ref-heartprotectionstudycollaborativegroupRandomizedTrialEffects2007" role="doc-biblioref">Group, 2007</a>)</span></p></li>
</ul></li>
</ol>
<p>Non Modifiable:</p>
<ol style="list-style-type: decimal">
<li><p><strong>Age</strong></p>
<ul>
<li><p>Age is identified as a risk factor for PAD regardless of gender.</p></li>
<li><p>Prevalence of PAD increases with age: 15% &gt; 70 years of age.</p></li>
</ul></li>
<li><p><strong>Gender</strong></p>
<ul>
<li>The Framingham Study has found that the risk of developing PAD
is doubled in men.</li>
</ul></li>
<li><p><strong>Ethnicity</strong></p>
<ul>
<li><p>The MESA study showed a higher prevalence of PAD (ABPI &lt;0.9) in
African Americans compared to Whites. 7.2% versus 3.6%.
<span class="citation">(<a href="#ref-bildMultiEthnicStudyAtherosclerosis2002" role="doc-biblioref">Bild, 2002</a>)</span></p></li>
<li><p>Cross Sectional analysis 6653 subjects all with ABPI assessment
revealed a prevalence of PAD (&lt;0.9) of 4%. Non-Hispanic
Whites: 3.6%, Asian: 2%, African American: 7.2% and
Hispanic: 2.4%. (p&lt;0.01)
<span class="citation">(<a href="#ref-allisonEffectNovelCardiovascular2006" role="doc-biblioref">Allison et al., 2006</a>)</span></p></li>
</ul></li>
</ol>
<p><strong>What are the some of the major population-based trials looking at the
natural history?</strong></p>
<ol style="list-style-type: decimal">
<li><p>The Framingham Heart Study: The original Cohort from the town of
Framingham, n=5183 patients followed over time for over 30 years.
There have been multiple subsequent recruited populations since. The
majority of information we have about risk factors related to
cardiovascular health comes from this study.
<span class="citation">(<a href="#ref-mahmoodFraminghamHeartStudy2014" role="doc-biblioref">Mahmood et al., 2014</a>)</span></p></li>
<li><p>The Rotterdam Study: 1990, Longitudinal Study, &gt;7000 particpants.</p></li>
<li><p>CVHS – 1989-1999 Longitudinal Study : n&gt;5000 Multicentre Study.</p></li>
<li><p>MESA – Cross Sectional analysis 6653 subjects all with ABPI
assessment revealed a prevalence of PAD (&lt;0.9) of 4%. Non-Hispanic
Whites: 3.6%, Asian: 2%, African American: 7.2% and Hispanic: 2.4%.
(p&lt;0.01) <span class="citation">(<a href="#ref-allisonEffectNovelCardiovascular2006" role="doc-biblioref">Allison et al., 2006</a>)</span></p></li>
<li><p>The Edinburgh Study: The EAS began as a cross sectional study of
1592 men and women in Edinburgh with the goal of examining the
frequency of risk factors for peripheral arterial disease. The
subjects were followed over 20 years.
<span class="citation">(<a href="#ref-fowkesEdinburghArteryStudy1991" role="doc-biblioref">Fowkes et al., 1991</a>)</span></p></li>
</ol>
<p><strong>How does Diabetes confound the clinical picture of PAOD?</strong></p>
<ul>
<li><p>Increasing Incidence of Diabetes world-wide.
<span class="citation">(<a href="#ref-boultonGlobalBurdenDiabetic2005" role="doc-biblioref">Boulton et al., 2005</a>)</span></p>
<ul>
<li><p>2.8% in 2000, 4.4% in 2030</p></li>
<li><p>25% of patients with diabetes develop a DFU at some stage in
their lives</p></li>
<li><p>Limb Loss every 20 seconds world-wide to Diabetes</p></li>
</ul></li>
</ul>
<p><strong>What’s the pathophysiology of Diabetes and PAOD</strong>
<span class="citation">(<a href="#ref-armstrong26PathophysiologyPrinciplesManagement2012" role="doc-biblioref">Armstrong et al., 2012</a>)</span></p>
<ul>
<li><p>Sensory Neuropathy, Motor Neuropathy and Autonomic Neuropathy</p></li>
<li><p>Structural and Gait abnormalities</p></li>
<li><p>Arterial disease</p>
<ul>
<li><p>Large Vessel</p></li>
<li><p>Small Vessel</p></li>
<li><p>Both</p></li>
</ul></li>
</ul>
<p>Given this diverse and confounding pathology the normal progressive
history of PAD is somewhat different. What’s most concerning is the
neuropathy resulting in initial presentation being ulceration. This
results in a lack of a ‘safety net’ where presenting with progressive
claudication allows for a period of detection, management and and risk
factor modification before they develop tissue loss and are at risk of
amputation.</p>
<p>Since 2014 and the publication of WIfI a lot has changed in the way we view
PAD leading up to last years new Global Vascular Guidelines on CLTI, which as a term has replaced CLI. <span class="citation">(<a href="#ref-conteGlobalVascularGuidelines2019a" role="doc-biblioref">Conte et al., 2019</a>; <a href="#ref-millsSocietyVascularSurgery2014a" role="doc-biblioref">Mills et al., 2014</a>)</span></p>
</div>
<div id="intermittent-claudication" class="section level2" number="5.2">
<h2><span class="header-section-number">5.2</span> Intermittent Claudication</h2>
<p><strong>What is Intermittent Claudication and the classic patient
presentation?</strong></p>
<p>The original population studies we mentioned determined the epidemiology
and natural history of Intermittent Claudication based on historically
validated and widely accepted questionnaires, namely the Rose
<span class="citation">(<a href="#ref-roseDiagnosisIschaemicHeart1962" role="doc-biblioref">Rose, 1962</a>)</span> (which later was adopted by the WHO)
and subsequently the Edinburgh questionnaire
<span class="citation">(<a href="#ref-lendEdinburghClaudicationQuestionnaire1992" role="doc-biblioref">Lend &amp; Fowkes, 1992</a>)</span>.</p>
<p>All questionnaires are based on a number of key diagnostic clinical
factors that define claudication, they are:</p>
<ul>
<li><p>Onset</p></li>
<li><p>Calf involvement</p></li>
<li><p>Reproducibility</p></li>
<li><p>Relief with Rest</p></li>
<li><p>Not occurring at Rest</p></li>
</ul>
<p>The progression historically graded by Fontaine (1954)
<span class="citation">(<a href="#ref-fontaineSurgicalTreatmentPeripheral1954" role="doc-biblioref">Fontaine et al., 1954</a>)</span> followed by the Rutherford
Grading System (1986, Revised 1997)
<span class="citation">(<a href="#ref-rutherfordRecommendedStandardsReports1997" role="doc-biblioref">Rutherford et al., 1997</a>)</span></p>
<p>Rutherford et al. Ad Hoc Committee on Reporting Standards, SVS/North
American Chapter ISCVS:</p>
<table>
<thead>
<tr class="header">
<th>Grade/Category</th>
<th>Clinical Description</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>0/0</td>
<td>Asymptomatic -no haemodynamic significant occlusive disease</td>
</tr>
<tr class="even">
<td>I/1</td>
<td>Mild Claudication</td>
</tr>
<tr class="odd">
<td>I/2</td>
<td>Moderate Claudication</td>
</tr>
<tr class="even">
<td>I/3</td>
<td>Severe Claudication</td>
</tr>
<tr class="odd">
<td>II/4</td>
<td>Ischaemic Rest Pain</td>
</tr>
<tr class="even">
<td>III/5</td>
<td>Minor Tissue Loss</td>
</tr>
<tr class="odd">
<td>III/6</td>
<td>Major Tissue Loss</td>
</tr>
</tbody>
</table>
<p><strong>What is involved in the work up of patients with PAOD/Intermittent
Claudication?</strong></p>
<div id="history-clinical-examination" class="section level3" number="5.2.1">
<h3><span class="header-section-number">5.2.1</span> History / Clinical Examination</h3>
<p>SVS Guidelines:</p>
<p>“We recommend using ABI as the first-line non-invasive test to establish
a diagnosis of PAD in individuals with symptoms or signs suggestive of
disease. When the ABI is borderline or normal (&gt;0.9) and symptoms of
claudication are suggestive, we recommend an exercise ABI.”</p>
<p><em>Grade 1 Level of Evidence A</em></p>
<ul>
<li><p>ABPI</p></li>
<li><p>Exercise ABPI</p></li>
<li><p>Ultrasound</p></li>
</ul>
<p><strong>What is an ABPI and how is it measured?</strong></p>
<p>The AHA came out with guidelines on how to perform an ABI and to
standardise the method to allow for more comparable results from
studies.</p>
<p>Divide the higher of the PT or DP pressure by the higher of the right or
left Brachial SBP<em>(Class 1 Level of Evidence A)</em>
<span class="citation">(<a href="#ref-aboyansMeasurementInterpretationAnkleBrachial2012" role="doc-biblioref">Aboyans et al., 2012</a>)</span></p>
<p>Sensitivity and Specificity both &gt;95% (when ABPI cut off &lt;/=0.9 – in
detecting &gt;/= 50% stenosis) <span class="citation">(<a href="#ref-ourielCriticalEvaluationStress1982" role="doc-biblioref">Ouriel et al., 1982</a>; <a href="#ref-yaoAnkleSystolicPressure2005" role="doc-biblioref">Yao et al., 2005</a>)</span></p>
<table>
<thead>
<tr class="header">
<th><strong>Interpreting ABPI</strong></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>&gt;1.4</td>
</tr>
<tr class="even">
<td>&gt;0.9-1.39</td>
</tr>
<tr class="odd">
<td>0.5-0.9</td>
</tr>
<tr class="even">
<td>0.0-0.5</td>
</tr>
</tbody>
</table>
<p><strong>What is Exercise ABPI studies?</strong></p>
<p>Constant Load Testing – (unlike the Graded Test – Bruce Protocol)</p>
<p>Walking distance has been shown to correlate with level and severity of
POAD. <span class="citation">(<a href="#ref-strandnessHemodynamicsSurgeons1975a" role="doc-biblioref">Strandness &amp; Sumner, 1975</a>)</span></p>
<p><strong>What is the ultrasound duplex criteria for defining PAOD?</strong></p>
<table style="width:94%;">
<colgroup>
<col width="19%" />
<col width="29%" />
<col width="19%" />
<col width="26%" />
</colgroup>
<thead>
<tr class="header">
<th>Stenosis
Category</th>
<th>Peak Systolic
Velocity</th>
<th>Velocity
Ratio</th>
<th>Distal Artery
Spectral
Waveform</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Normal</td>
<td>&lt;150</td>
<td>&lt;1.5</td>
<td>Triphasic,
Normal PSV</td>
</tr>
<tr class="even">
<td>30-49%</td>
<td>150-200</td>
<td>1.5-2</td>
<td>Triphasic,
Normal PSV</td>
</tr>
<tr class="odd">
<td>50-75%</td>
<td>200-400</td>
<td>2-4</td>
<td>Monophasic,
reduced PSV</td>
</tr>
<tr class="even">
<td>&gt;75%</td>
<td>&gt;400</td>
<td>&gt;4</td>
<td>Damped,
monophasic,
reduced PSV</td>
</tr>
<tr class="odd">
<td>Occlusion</td>
<td>No Flow – B
-mode, Terminal
Thump</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
<p>Adapted from <span class="citation">(<a href="#ref-stone21VascularLaboratory2019" role="doc-biblioref">Stone &amp; Hass, 2019</a>)</span></p>
<p><strong>What Guidelines are there pertaining to PAD Management.</strong></p>
<p>SVS Guidelines (2015)</p>
<ul>
<li>The SVS published the SVS practice guidelines for atherosclerotic
occlusive disease of the lower extremities:<strong>Management of asymptomatic disease and claudication</strong>. <em>Conte and Pomposelli et al. JVS 2015</em> <span class="citation">(<a href="#ref-conteSocietyVascularSurgery2015" role="doc-biblioref">Conte et al., 2015</a>)</span></li>
</ul>
<p>Other Guidelines:</p>
<ul>
<li><p>TASC 1 -2</p></li>
<li><p>European Guidelines (2017)</p></li>
<li><p>AHA Guidelines (last update 2016)</p></li>
</ul>
<p><strong>What is the initial management of Asymptomatic Patients with PAD?</strong></p>
<ol style="list-style-type: decimal">
<li>Smoking Cessation – Multidisciplinary comprehensive smoking
cessation interventions – repeatedly until tobacco use has stopped
(Grade A – 1)</li>
<li>Intervention is not only not recommended, but invasive treatment is
recommended against, in the absence of symptoms (Grade A -1)</li>
</ol>
<p><strong>How can we medically (non-invasively) manage Asymptomatic PAOD based
on the SVS Guidelines?</strong></p>
<ul>
<li><p>Anti-platelet Therapy</p>
<ul>
<li>The Aspirin for Asymptomatic Atherosclerosis Trial – n=3350,
aspirin versus placebo. 8 years follow up no difference in
events <span class="citation">(<a href="#ref-fowkesAspirinPreventionCardiovascular2010" role="doc-biblioref">Fowkes, 2010</a>)</span> – therefore
benefit unknown</li>
</ul></li>
<li><p>Statin Therapy</p>
<ul>
<li><p>The Heart Protection Study <span class="citation">(<a href="#ref-heartprotectionstudycollaborativegroupRandomizedTrialEffects2007" role="doc-biblioref">Group, 2007</a>)</span> - this
study looked at Statins in patients with PAD but not completely
asymptomatic, they had other risk factors such as diabetes, IHD,
cerebral disease or hypertension. Without these risk factors
Statin therapy benefit unsure.</p></li>
<li><p>However, the AHA from the Framingham Study does recommend using
Statins if 10-year risk based on risk calculators &gt;7.5% (which
would be positive if PAD present).</p></li>
</ul></li>
<li><p>Exercise and Limb Function</p>
<ul>
<li>No clear evidence that physical therapy improves QoL</li>
</ul></li>
<li><p>Surveillance</p>
<ul>
<li>No benefit from US surveillance, unclear benefit of ABPI
surveillance.</li>
</ul></li>
</ul>
</div>
<div id="management-2" class="section level3" number="5.2.2">
<h3><span class="header-section-number">5.2.2</span> Management</h3>
<p><strong>How can we medically manage Intermittent Claudication based on the SVS
Guidelines?</strong></p>
<ul>
<li><p>Smoking Cessation – Multidisciplinary comprehensive smoking
cessation interventions – repeatedly until tobacco use has stopped
(Grade A – 1)</p></li>
<li><p>Dyslipidaemia: Statin Therapy Recommended – most recent evidence on
lipid therapy has suggested focussing on reducing 10-year
cardiovascular event risk rather than specifically reducing lipid
levels. (Grade 1-A)</p></li>
<li><p>Statin Therapy – Aspirin therapy (75-325mg daily) is recommended to
reduce cardiovascular events in patients with PAD (Grade 1-Level A)
<span class="citation">(<a href="#ref-collaborationCollaborativeMetaanalysisRandomised2002" role="doc-biblioref">Collaboration, 2002</a>)</span></p>
<ul>
<li>There is evidence that Clopidogrel 75mg compared to Aspirin is
better in event reduction
(CAPRIE)<span class="citation">(<a href="#ref-capriesteeringcommitteeRandomisedBlindedTrial1996" role="doc-biblioref">Committee, 1996</a>)</span>–
replacing Aspirin with Clopidogrel Grade 1-Level B)</li>
</ul></li>
<li><p>Diabetes Mellitus – Optimisation of HbA1C &lt; 7% (Grade 1-Level B)</p></li>
<li><p>Hypertension – Indicated B-Blockers for hypertension (Grade
1-Level B) (there’s no evidence that Beta Blockers worsens IC)</p></li>
<li><p>Homocysteine – Recommendation against Folic Acid and Vit B12 (
Grade 2 – C)</p></li>
</ul>
<p><strong>To improve Limb Function in patients with IC:</strong></p>
<ul>
<li><p>Cilostozol use – IC without CHF – 3-month Trial (Grade 2 - A)</p>
<ul>
<li><p>If unable to tolerate Cilostozol – Pentoxifylline (400mg TDS)
(Grade 2 – B)</p></li>
<li><p>Based on Meta-analysis 26 trials
<span class="citation">(<a href="#ref-stevensSystematicReviewEfficacy2012" role="doc-biblioref">Stevens et al., 2012</a>)</span></p></li>
</ul></li>
<li><p>Exercise Therapy</p>
<ul>
<li><p>First Line Therapy recommended SEP: minimum three times / week
(30-60 min/session) for at least 12 weeks (Grade 1 Level A)</p></li>
<li><p>Meta-analysis of 32 RCT’s: Placebo versus exercise: Walking
Time, Walking Ability, Pain Free Walking and maximum walking
distance improves. BUT no difference in ABPI, Mortality or
amputation. <span class="citation">(<a href="#ref-laneExerciseIntermittentClaudication2017" role="doc-biblioref">Lane et al., 2017</a>)</span></p></li>
<li><p>Meta- Analysis of 14RCT’s: SEP better than Non-Supervised
Programs. <span class="citation">(<a href="#ref-hagemanSupervisedExerciseTherapy2018" role="doc-biblioref">Hageman et al., 2018</a>)</span></p></li>
</ul></li>
</ul>
<p><strong>What is the management for patients with Intermittent Claudication?</strong></p>
<ul>
<li><p><strong>Patient Selection for Intervention:</strong></p>
<ul>
<li><p>20-30% of patients with IC who adhere to risk factor
modification will have progressive symptoms that will eventually
be treated with intervention.</p></li>
<li><p>Patient selection should be based on QoL and functional
impairment in an active person (loss of ability to perform
occupation or that limits basic activities of daily living)
rather than haemodynamic (ABPI or US) or anatomical disease
progression/severity.</p></li>
</ul></li>
<li><p><strong>Always remember multifactorial causes of immobility –
particularly in the elderly.</strong></p>
<ul>
<li>SVS recommends that invasive therapy for IC have a &gt;50%
likelihood of sustained clinical improvement for at least 2
years.</li>
</ul></li>
<li><p><strong>Anatomical Selection:</strong></p>
<ul>
<li><p>Aortoiliac Disease:</p>
<ul>
<li><p>Previous TASC Classification has attempted to categorise
anatomy of disease and subsequent recommendation of
Endovascular versus open surgery. But as the authors of the
SVS guidelines highlight, “improvements in technology and
endovascular techniques have resulted in EVT replacing open
surgical bypass as a primary treatment for both focal and
advanced AIOD in many cases.”</p></li>
<li><p>The majority of evidence is non randomized and meta analyses
of non-randomized series.</p></li>
<li><p>Endovascular procedures over open surgery for focal AIOD
causing IC. (Grade 1 Evidence B)</p></li>
<li><p>Endovascular interventions as first line for CIA or EIZ
occlusive disease-causing IC. (Grade 1 Level B)</p></li>
<li><p>Hybrid recommended for Iliac disease involving CFA. (Grade 1
Level B)</p></li>
<li><p>Direct Surgical reconstruction (bypass, endarterectomy) in
patients with reasonable surgical risk and diffuse AIOD not
amenable to endovascular approach, after one or more failed
attempts at EVT, or combined occlusive and aneurysmal
disease. (Grade 1 Evidence B)</p></li>
</ul></li>
<li><p>Infrainguinal Disease:</p>
<ul>
<li><p>When you look at the historical data comparing all EVT
together they are less durable than surgical bypass,
especially when there’s diffuse or long segments of
occlusion/multilevel infra inguinal disease.</p></li>
<li><p>Most recommendations are based on low level evidence when
comparing EVT versus Open Surgery</p></li>
<li><p>Focal + Not involving SFA origin = EVT (Grade 1 Level C)</p></li>
<li><p>SFA 5-15cm, self-expanding stent (with or without
paclitaxel) (Grade 1 Level B) – NB: (This was in 2015 pre
Katsanos Paper)</p></li>
<li><p>Recommend against infrapopliteal treatment for IC (Grade 1
Level C)</p></li>
<li><p>Initial Surgical Bypass (with vein: Grade 1 Level a): If</p>
<ul>
<li><p>Diffuse FP disease</p></li>
<li><p>Small Calibre &lt;5mm</p></li>
<li><p>Extensive calcification in SFA</p></li>
<li><p>Average or low operative risk (Grade 1 Level B)</p></li>
</ul></li>
</ul></li>
</ul></li>
</ul>

</div>
</div>
</div>
<h3>References</h3>
<div id="refs" class="references csl-bib-body hanging-indent" line-spacing="2">
<div id="ref-aboyansMeasurementInterpretationAnkleBrachial2012" class="csl-entry">
Aboyans, V., Criqui, M. H., Abraham, P., Allison, M. A., Creager, M. A., Diehm, C., Fowkes, F. G. R., Hiatt, W. R., Jönsson, B., Lacroix, P., Marin, B., McDermott, M. M., Norgren, L., Pande, R. L., Preux, P.-M., Stoffers, H. E. (Jelle)., &amp; Treat-Jacobson, D. (2012). Measurement and <span>Interpretation</span> of the <span>Ankle-Brachial Index</span>: <span>A Scientific Statement From</span> the <span>American Heart Association</span>. <em>Circulation</em>, <em>126</em>(24), 2890–2909. <a href="https://doi.org/10.1161/CIR.0b013e318276fbcb">https://doi.org/10.1161/CIR.0b013e318276fbcb</a>
</div>
<div id="ref-aboyans2017ESCGuidelines2018" class="csl-entry">
Aboyans, V., Ricco, J.-B., Bartelink, M.-L. E. L., Björck, M., Brodmann, M., Cohnert, T., Collet, J.-P., Czerny, M., De Carlo, M., Debus, S., Espinola-Klein, C., Kahan, T., Kownator, S., Mazzolai, L., Naylor, A. R., Roffi, M., Röther, J., Sprynger, M., Tendera, M., … Obiekezie, A. (2018). 2017 <span>ESC Guidelines</span> on the <span>Diagnosis</span> and <span>Treatment</span> of <span>Peripheral Arterial Diseases</span>, in collaboration with the <span>European Society</span> for <span>Vascular Surgery</span> (<span>ESVS</span>). <em>European Heart Journal</em>, <em>39</em>(9), 763–816. <a href="https://doi.org/10.1093/eurheartj/ehx095">https://doi.org/10.1093/eurheartj/ehx095</a>
</div>
<div id="ref-adlerUKPDS59Hyperglycemia2002" class="csl-entry">
Adler, A. I., Stevens, R. J., Neil, A., Stratton, I. M., Boulton, A. J. M., Holman, R. R., &amp; for the U.K. Prospective Diabetes Study Group. (2002). <span>UKPDS</span> 59: <span>Hyperglycemia</span> and <span>Other Potentially Modifiable Risk Factors</span> for <span>Peripheral Vascular Disease</span> in <span>Type</span> 2 <span>Diabetes</span>. <em>Diabetes Care</em>, <em>25</em>(5), 894–899. <a href="https://doi.org/10.2337/diacare.25.5.894">https://doi.org/10.2337/diacare.25.5.894</a>
</div>
<div id="ref-allisonEffectNovelCardiovascular2006" class="csl-entry">
Allison, M. A., Criqui, M. H., McClelland, R. L., Scott, J. M., McDermott, M. M., Liu, K., Folsom, A. R., Bertoni, A. G., Sharrett, A. R., Homma, S., &amp; Kori, S. (2006). The <span>Effect</span> of <span>Novel Cardiovascular Risk Factors</span> on the <span>Ethnic-Specific Odds</span> for <span>Peripheral Arterial Disease</span> in the <span>Multi-Ethnic Study</span> of <span>Atherosclerosis</span> (<span>MESA</span>). <em>Journal of the American College of Cardiology</em>, <em>48</em>(6), 1190–1197. <a href="https://doi.org/10.1016/j.jacc.2006.05.049">https://doi.org/10.1016/j.jacc.2006.05.049</a>
</div>
<div id="ref-armstrong26PathophysiologyPrinciplesManagement2012" class="csl-entry">
Armstrong, D. L., Fisher, T. K., Lepow, B., White, M. L., &amp; Mills, J. L. (2012). <span>26Pathophysiology</span> and <span>Principles</span> of <span>Management</span> of the <span>Diabetic Foot</span>. In <em>Mechanisms of <span>Vascular Disease</span>: <span>A Reference Book</span> for <span>Vascular Specialists</span></em>. <span>University of Adelaide Press</span>. <a href="https://doi.org/10.1017/UPO9781922064004">https://doi.org/10.1017/UPO9781922064004</a>
</div>
<div id="ref-bildMultiEthnicStudyAtherosclerosis2002" class="csl-entry">
Bild, D. E. (2002). Multi-<span>Ethnic Study</span> of <span>Atherosclerosis</span>: <span>Objectives</span> and <span>Design</span>. <em>American Journal of Epidemiology</em>, <em>156</em>(9), 871–881. <a href="https://doi.org/10.1093/aje/kwf113">https://doi.org/10.1093/aje/kwf113</a>
</div>
<div id="ref-boultonGlobalBurdenDiabetic2005" class="csl-entry">
Boulton, A. J., Vileikyte, L., Ragnarson-Tennvall, G., &amp; Apelqvist, J. (2005). The global burden of diabetic foot disease. <em>The Lancet</em>, <em>366</em>(9498), 1719–1724. <a href="https://doi.org/10.1016/S0140-6736(05)67698-2">https://doi.org/10.1016/S0140-6736(05)67698-2</a>
</div>
<div id="ref-collaborationCollaborativeMetaanalysisRandomised2002" class="csl-entry">
Collaboration, A. T. (2002). Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. <em>BMJ : British Medical Journal</em>, <em>324</em>(7329), 71–86.
</div>
<div id="ref-capriesteeringcommitteeRandomisedBlindedTrial1996" class="csl-entry">
Committee, C. S. (1996). A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (<span>CAPRIE</span>). <em>The Lancet</em>, <em>348</em>(9038), 1329–1339. <a href="https://doi.org/10.1016/S0140-6736(96)09457-3">https://doi.org/10.1016/S0140-6736(96)09457-3</a>
</div>
<div id="ref-conteGlobalVascularGuidelines2019a" class="csl-entry">
Conte, M. S., Bradbury, A. W., Kolh, P., White, J. V., Dick, F., Fitridge, R., Mills, J. L., Ricco, J.-B., Suresh, K. R., &amp; Murad, M. H. (2019). Global vascular guidelines on the management of chronic limb-threatening ischemia. <em>European Journal of Vascular and Endovascular Surgery : The Official Journal of the European Society for Vascular Surgery</em>, <em>58</em>(1 Suppl), S1–S109.e33. <a href="https://doi.org/10.1016/j.ejvs.2019.05.006">https://doi.org/10.1016/j.ejvs.2019.05.006</a>
</div>
<div id="ref-conteSocietyVascularSurgery2015" class="csl-entry">
Conte, M. S., Pomposelli, F. B., Clair, D. G., Geraghty, P. J., McKinsey, J. F., Mills, J. L., Moneta, G. L., Murad, M. H., Powell, R. J., Reed, A. B., Schanzer, A., &amp; Sidawy, A. N. (2015). Society for <span>Vascular Surgery</span> practice guidelines for atherosclerotic occlusive disease of the lower extremities: <span>Management</span> of asymptomatic disease and claudication. <em>Journal of Vascular Surgery</em>, <em>61</em>(3), 2S–41S.e1. <a href="https://doi.org/10.1016/j.jvs.2014.12.009">https://doi.org/10.1016/j.jvs.2014.12.009</a>
</div>
<div id="ref-fontaineSurgicalTreatmentPeripheral1954" class="csl-entry">
Fontaine, R., Kim, M., &amp; Kieny, R. (1954). <span>[Surgical treatment of peripheral circulation disorders]</span>. <em>Helvetica Chirurgica Acta</em>, <em>21</em>(5-6), 499–533.
</div>
<div id="ref-fowkesAspirinPreventionCardiovascular2010" class="csl-entry">
Fowkes, F. G. R. (2010). Aspirin for <span>Prevention</span> of <span>Cardiovascular Events</span> in a <span>General Population Screened</span> for a <span>Low Ankle Brachial IndexA Randomized Controlled Trial</span>. <em>JAMA</em>, <em>303</em>(9), 841. <a href="https://doi.org/10.1001/jama.2010.221">https://doi.org/10.1001/jama.2010.221</a>
</div>
<div id="ref-fowkesEdinburghArteryStudy1991" class="csl-entry">
Fowkes, F. G. R., Housley, E., Cawood, E. H. H., Macintyre, C. C. A., Ruckley, C. V., &amp; Prescott, R. J. (1991). Edinburgh <span>Artery Study</span>: <span>Prevalence</span> of <span>Asymptomatic</span> and <span>Symptomatic Peripheral Arterial Disease</span> in the <span>General Population</span>. <em>International Journal of Epidemiology</em>, <em>20</em>(2), 384–392. <a href="https://doi.org/10.1093/ije/20.2.384">https://doi.org/10.1093/ije/20.2.384</a>
</div>
<div id="ref-gordonPredispositionAtherosclerosisHead1972" class="csl-entry">
Gordon, T., &amp; Kannel, W. B. (1972). Predisposition to atherosclerosis in the head, heart, and legs. <span>The Framingham</span> study. <em>JAMA</em>, <em>221</em>(7), 661–666.
</div>
<div id="ref-heartprotectionstudycollaborativegroupRandomizedTrialEffects2007" class="csl-entry">
Group, H. P. S. C. (2007). Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions. <em>Journal of Vascular Surgery</em>, <em>45</em>(4), 645–654.e1. <a href="https://doi.org/10.1016/j.jvs.2006.12.054">https://doi.org/10.1016/j.jvs.2006.12.054</a>
</div>
<div id="ref-hagemanSupervisedExerciseTherapy2018" class="csl-entry">
Hageman, D., Fokkenrood, H. J., Gommans, L. N., van den Houten, M. M., &amp; Teijink, J. A. (2018). Supervised exercise therapy versus home-based exercise therapy versus walking advice for intermittent claudication. <em>The Cochrane Database of Systematic Reviews</em>, <em>2018</em>(4), CD005263. <a href="https://doi.org/10.1002/14651858.CD005263.pub4">https://doi.org/10.1002/14651858.CD005263.pub4</a>
</div>
<div id="ref-kannelUpdateEpidemiologicFeatures1985" class="csl-entry">
Kannel, W. B., &amp; McGee, D. L. (1985). Update on some epidemiologic features of intermittent claudication: The <span>Framingham Study</span>. <em>Journal of the American Geriatrics Society</em>, <em>33</em>(1), 13–18. <a href="https://doi.org/10.1111/j.1532-5415.1985.tb02853.x">https://doi.org/10.1111/j.1532-5415.1985.tb02853.x</a>
</div>
<div id="ref-laneExerciseIntermittentClaudication2017" class="csl-entry">
Lane, R., Harwood, A., Watson, L., &amp; Leng, G. C. (2017). Exercise for intermittent claudication. <em>The Cochrane Database of Systematic Reviews</em>, <em>2017</em>(12), CD000990. <a href="https://doi.org/10.1002/14651858.CD000990.pub4">https://doi.org/10.1002/14651858.CD000990.pub4</a>
</div>
<div id="ref-lendEdinburghClaudicationQuestionnaire1992" class="csl-entry">
Lend, G. C., &amp; Fowkes, F. G. R. (1992). The <span>Edinburgh Claudication Questionnaire</span>: <span>An</span> improved version of the <span>WHO</span>/<span>Rose</span> questionnaire for use in epidemiological surveys. <em>Journal of Clinical Epidemiology</em>, <em>45</em>(10), 1101–1109. <a href="https://doi.org/10.1016/0895-4356(92)90150-L">https://doi.org/10.1016/0895-4356(92)90150-L</a>
</div>
<div id="ref-mahmoodFraminghamHeartStudy2014" class="csl-entry">
Mahmood, S. S., Levy, D., Vasan, R. S., &amp; Wang, T. J. (2014). The <span>Framingham Heart Study</span> and the <span>Epidemiology</span> of <span>Cardiovascular Diseases</span>: <span>A Historical Perspective</span>. <em>Lancet</em>, <em>383</em>(9921), 999–1008. <a href="https://doi.org/10.1016/S0140-6736(13)61752-3">https://doi.org/10.1016/S0140-6736(13)61752-3</a>
</div>
<div id="ref-millsSocietyVascularSurgery2014a" class="csl-entry">
Mills, J. L., Conte, M. S., Armstrong, D. G., Pomposelli, F. B., Schanzer, A., Sidawy, A. N., &amp; Andros, G. (2014). The <span>Society</span> for <span>Vascular Surgery Lower Extremity Threatened Limb Classification System</span>: <span>Risk</span> stratification based on <span>Wound</span>, <span>Ischemia</span>, and foot <span>Infection</span> (<span>WIfI</span>). <em>Journal of Vascular Surgery</em>, <em>59</em>(1), 220–234.e2. <a href="https://doi.org/10.1016/j.jvs.2013.08.003">https://doi.org/10.1016/j.jvs.2013.08.003</a>
</div>
<div id="ref-ourielCriticalEvaluationStress1982" class="csl-entry">
Ouriel, K., McDonnell, A. E., Metz, C. E., &amp; Zarins, C. K. (1982). Critical evaluation of stress testing in the diagnosis of peripheral vascular disease. <em>Surgery</em>, <em>91</em>(6), 686–693.
</div>
<div id="ref-roseDiagnosisIschaemicHeart1962" class="csl-entry">
Rose, G. A. (1962). The diagnosis of ischaemic heart pain and intermittent claudication in field surveys. <em>Bulletin of the World Health Organization</em>, <em>27</em>(6), 645–658.
</div>
<div id="ref-rutherfordRecommendedStandardsReports1997" class="csl-entry">
Rutherford, R. B., Baker, J. D., Ernst, C., Johnston, K. W., Porter, J. M., Ahn, S., &amp; Jones, D. N. (1997). Recommended standards for reports dealing with lower extremity ischemia: <span>Revised</span> version. <em>Journal of Vascular Surgery</em>, <em>26</em>(3), 517–538. <a href="https://doi.org/10.1016/S0741-5214(97)70045-4">https://doi.org/10.1016/S0741-5214(97)70045-4</a>
</div>
<div id="ref-stevensSystematicReviewEfficacy2012" class="csl-entry">
Stevens, J. W., Simpson, E., Harnan, S., Squires, H., Meng, Y., Thomas, S., Michaels, J., &amp; Stansby, G. (2012). Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication. <em>British Journal of Surgery</em>, <em>99</em>(12), 1630–1638. <a href="https://doi.org/10.1002/bjs.8895">https://doi.org/10.1002/bjs.8895</a>
</div>
<div id="ref-stone21VascularLaboratory2019" class="csl-entry">
Stone, P. A., &amp; Hass, S. M. (2019). 21. <span>Vascular Laboratory</span>: <span>Arterial Duplex Scanning</span>. In <em>Rutherford’s <span>Vascular Surgery</span> and <span>Endovascular Therapy</span></em> (Ninth). <span>Elsevier Inc.</span> <a href="https://doi.org/10.1016/B978-0-323-42791-3.00021-9">https://doi.org/10.1016/B978-0-323-42791-3.00021-9</a>
</div>
<div id="ref-strandnessHemodynamicsSurgeons1975a" class="csl-entry">
Strandness, D. E., &amp; Sumner, D. S. (1975). <em>Hemodynamics for surgeons</em>. <span>Grune &amp; Stratton</span>.
</div>
<div id="ref-unitedstatessurgeongeneralHealthConsequencesSmoking2014" class="csl-entry">
United States Surgeon General. (2014). <em>The <span>Health Consequences</span> of <span>Smoking</span> – 50 <span>Years</span> of progress: <span>A Report</span> of the <span>Surgeon General</span>: (510072014-001)</em>. <span>American Psychological Association</span>. <a href="https://doi.org/10.1037/e510072014-001">https://doi.org/10.1037/e510072014-001</a>
</div>
<div id="ref-yaoAnkleSystolicPressure2005" class="csl-entry">
Yao, S. T., Hobbs, J. T., &amp; Irivne, W. T. (2005). Ankle systolic pressure measurements in arterial disease affecting the lower extremities. <em>British Journal of Surgery</em>, <em>56</em>(9), 676–679. <a href="https://doi.org/10.1002/bjs.1800560910">https://doi.org/10.1002/bjs.1800560910</a>
</div>
</div>
            </section>

          </div>
        </div>
      </div>
<a href="abdominaliliacperipheral-aneurysms.html" class="navigation navigation-prev " aria-label="Previous page"><i class="fa fa-angle-left"></i></a>
<a href="mesenteric-disease.html" class="navigation navigation-next " aria-label="Next page"><i class="fa fa-angle-right"></i></a>
    </div>
  </div>
<script src="libs/gitbook-2.6.7/js/app.min.js"></script>
<script src="libs/gitbook-2.6.7/js/clipboard.min.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-search.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-sharing.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-fontsettings.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-bookdown.js"></script>
<script src="libs/gitbook-2.6.7/js/jquery.highlight.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-clipboard.js"></script>
<script>
gitbook.require(["gitbook"], function(gitbook) {
gitbook.start({
"sharing": {
"github": false,
"facebook": true,
"twitter": true,
"linkedin": false,
"weibo": false,
"instapaper": false,
"vk": false,
"whatsapp": false,
"all": ["facebook", "twitter", "linkedin", "weibo", "instapaper"]
},
"fontsettings": {
"theme": "white",
"family": "sans",
"size": 2
},
"edit": {
"link": "https://github.com/adam-mdmph/VS-Board-Review/blob/main/04-lower-extremity-occlusive.Rmd",
"text": "Edit"
},
"history": {
"link": null,
"text": null
},
"view": {
"link": null,
"text": null
},
"download": ["_main.pdf"],
"search": {
"engine": "fuse",
"options": null
},
"toc": {
"collapse": "section",
"scroll_highlight": true
}
});
});
</script>

<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    var src = "true";
    if (src === "" || src === "true") src = "https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-MML-AM_CHTML";
    if (location.protocol !== "file:")
      if (/^https?:/.test(src))
        src = src.replace(/^https?:/, '');
    script.src = src;
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>
</body>

</html>
